Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azathioprine for Relapse Prevention in MOGAD
NCT05349006Phase 3Recruiting
- Sponsor
- Hospices Civils de Lyon
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) comparing Azathioprine with Placebo (2 arms). Primary endpoint: Time to first relapse at 3 years. Started Dec 2023; status: recruiting.
02
Drugs
azathioprine
03
Conditions
myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
Beyond the preview
Go deeper on NCT05349006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05349006.